利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.019 秒)

    Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
    3.
    发明申请
    Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots 审中-公开
    闭塞性血块裂解的方法，装置和组合物，同时节省伤口密封凝块

    公开(公告)号：US20070148160A1

    公开(公告)日：2007-06-28

    申请号：US11447455

    申请日：2006-06-06

    申请人： Victor Gurewich ,  Jian-Ning Liu ,  Paolo Sarmientos

    发明人： Victor Gurewich ,  Jian-Ning Liu ,  Paolo Sarmientos

    IPC分类号： A61K38/48

    CPC分类号： A61L29/16 ,  A61K38/00 ,  A61L31/16 ,  A61L33/0047 ,  A61L2300/254 ,  C12N9/6462 ,  C12Y304/21073

    摘要： It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

    摘要翻译： 现在已经发现，某些突变形式的前尿激酶（“pro-UK”），例如所谓的pro-UK突变体“M5”（Lys.sup.300.fwdarw.His））以这种方式 亲英国在裂解“不良”血块（堵塞血管的血块），同时将所谓“良好”血块中的止血纤维蛋白（例如手术或其他组织损伤后的血栓密封） 。 因此，这些pro-UK突变体是优秀和安全的溶栓剂。 这些优点使得它们可用于在临床情况下可用于溶栓和治疗各种心血管疾病的各种新方法，装置和组合物中，其中施用其它已知溶栓剂的风险太高或甚至禁忌。

    Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
    4.
    发明授权
    Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots 有权
    闭塞性血块裂解的方法，装置和组合物，同时节省伤口密封凝块

    公开(公告)号：US07074401B2

    公开(公告)日：2006-07-11

    申请号：US10826826

    申请日：2004-04-16

    申请人： Victor Gurewich ,  John N. Williams ,  Jian-Ning Liu ,  Paolo Sarmientos ,  Massimiliano Pagani

    发明人： Victor Gurewich ,  John N. Williams ,  Jian-Ning Liu ,  Paolo Sarmientos ,  Massimiliano Pagani

    IPC分类号： A61K38/49 ,  A61K38/36 ,  C12N9/72 ,  C12N9/64 ,  C07H21/04

    CPC分类号： A61L29/16 ,  A61K38/00 ,  A61L31/16 ,  A61L33/0047 ,  A61L2300/254 ,  C12N9/6462 ,  C12Y304/21073

    摘要： It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys300→His), perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

    摘要翻译： 现在已经发现，某些突变形式的前尿激酶（“pro-UK”），例如所谓的pro-UK突变体“M5”（Lys 300> His），在 亲英国在裂解“不良”血块（堵塞血管的血块）的方式，同时在所谓的“良好”血块（即手术或其他组织中密封伤口的血栓）节省止血纤维蛋白 伤害）。 因此，这些pro-UK突变体是优秀和安全的溶栓剂。 这些优点使得它们可用于在临床情况下可用于溶栓和治疗各种心血管疾病的各种新方法，装置和组合物中，其中施用其它已知溶栓剂的风险太高或甚至禁忌。

    Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
    5.
    发明申请
    Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots 审中-公开
    方法，装置和组合物用于闭塞性血栓的裂解，同时保持伤口密封

    公开(公告)号：US20090226410A1

    公开(公告)日：2009-09-10

    申请号：US12165082

    申请日：2008-06-30

    申请人： Victor Gurewich ,  Jian-Ning Liu ,  Paolo Sarmientos

    发明人： Victor Gurewich ,  Jian-Ning Liu ,  Paolo Sarmientos

    IPC分类号： A61K38/45 ,  A61P9/00

    CPC分类号： A61L29/16 ,  A61K38/00 ,  A61L31/16 ,  A61L33/0047 ,  A61L2300/254 ,  C12N9/6462 ,  C12Y304/21073

    摘要： It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

    摘要翻译： 现在已经发现，某些突变形式的前尿激酶（“pro-UK”），例如所谓的pro-UK突变体“M5”（Lys.sup.300.fwdarw.His））以这种方式 亲英国在裂解“不良”血块（堵塞血管的血块），同时将所谓“良好”血块中的止血纤维蛋白（例如手术或其他组织损伤后的血栓密封） 。 因此，这些pro-UK突变体是优秀和安全的溶栓剂。 这些优点使得它们可用于在临床情况下可用于溶栓和治疗各种心血管疾病的各种新方法，装置和组合物中，其中施用其它已知溶栓剂的风险太高或甚至禁忌。

    Methods of making pro-urokinase mutants
    7.
    发明申请
    Methods of making pro-urokinase mutants 失效
    制备尿激酶突变体的方法

    公开(公告)号：US20050019863A1

    公开(公告)日：2005-01-27

    申请号：US10826598

    申请日：2004-04-16

    申请人： Paolo Sarmientos ,  Massimiliano Pagani

    发明人： Paolo Sarmientos ,  Massimiliano Pagani

    IPC分类号： C07H21/04 ,  C12N9/72 ,  C12P21/02

    CPC分类号： C12N15/70 ,  C12N9/6462 ,  C12P21/02 ,  C12Y304/21073

    摘要： Methods are provided for producing non-glycosylated, single-chain and two-chain pro-urokinase (pro-UK) mutants. The methods include cultivating a specific E. coli type B strain that has been transformed with specific plasmids carrying a cDNA sequence that encodes pro-UK mutants and carries specific promoter sequences. Products produced by the methods have medical use for thrombolysis performed while sparing hemostatic clots, e.g., for particular applications such as after a stroke or heart attack.

    摘要翻译： 提供了用于生产非糖基化，单链和双链原尿激酶（pro-UK）突变体的方法。 所述方法包括培养已经用携带编码前UK突变体并携带特异性启动子序列的cDNA序列的特异性质粒转化的特异性大肠杆菌B型菌株。 通过该方法生产的产品具有医疗用途，用于在止血止血时进行溶栓治疗，例如用于特定应用例如中风或心脏病发作之后。

    Methods of making pro-urokinase mutants
    9.
    发明授权
    Methods of making pro-urokinase mutants 失效
    制备尿激酶突变体的方法

    公开(公告)号：US07070958B2

    公开(公告)日：2006-07-04

    申请号：US10826598

    申请日：2004-04-16

    申请人： Paolo Sarmientos ,  Massimiliano Pagani

    发明人： Paolo Sarmientos ,  Massimiliano Pagani

    IPC分类号： C12P21/06

    CPC分类号： C12N15/70 ,  C12N9/6462 ,  C12P21/02 ,  C12Y304/21073

    摘要： Methods are provided for producing non-glycosylated, single-chain and two-chain pro-urokinase (pro-UK) mutants. The methods include cultivating a specific E. coli type B strain that has been transformed with specific plasmids carrying a cDNA sequence that encodes pro-UK mutants and carries specific promoter sequences. Products produced by the methods have medical use for thrombolysis performed while sparing hemostatic clots, e.g., for particular applications such as after a stroke or heart attack.

    摘要翻译： 提供了用于生产非糖基化，单链和双链原尿激酶（pro-UK）突变体的方法。 所述方法包括培养已经用携带编码前UK突变体并携带特异性启动子序列的cDNA序列的特异性质粒转化的特异性大肠杆菌B型菌株。 通过该方法生产的产品具有医疗用途，用于在止血止血时进行溶栓治疗，例如用于特定应用例如中风或心脏病发作之后。